In APL, MNC from patients with a high-risk disease, classified according to the "Sanz score", tended to express FOXC1 at levels lower than those from patients with a low-intermediate risk APL, though the low number of high-risk APL tested might be too low to draw any conclusions (data not shown) [16]. This evidence concerns the gene FOXC1 and acute promyelocytic leukemia.